Shots:
- Kodiak has reported the P-III (DAYBREAK) trial data assessing Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in parallel vs aflibercept in pts with wet age-related macular degeneration (wAMD)
- Zenkuda met its 1EP, showing meaningful vision gains & rapid, sustained retinal drying, with 54% of pts achieving 6mos. durability at Yr. 1. tabirafusp-ted also met its vision 1EP & anatomical key 2EP
- Post-hoc analyses is planned to identify wAMD subgroups that may benefit from IL-6 inhibition, while P-III (ALTO) of KSI-501 for DME is currently enrolling. Kodiak plans to submit three-indication BLA for Zenkuda in Q4’26
Ref: PRnewswire | Image: Kodiak Sciences | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
